TradingView
RocketTickers
Oct 1, 2018 4:45 PM

SGEN Announce Positive Results from Phase 3 ECHELON-2 Clinical  Long

NASDAQ:SGEN1D

Description

⋅
2018-10-01 06:45:00
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Beyond Technical Analysis
More